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Summary Circulating forms of adhesion molecules (intercellular-adhesion molecule-
1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin ) are related
to the turnover of these molecules on the cell surface. In contrast to the other
molecules, the levels of E-selectin probably exclusively reflect the activity of
endothelial cells.
The aim of this study was to compare levels of circulating adhesion molecules in
patients with allergic (AA) and non-allergic asthma (NA) and to relate the levels of
soluble adhesion molecules to methacholine responsiveness and lung function.
The study comprised 19 patients with AA, 15 patients with NA and 17 healthy
subjects. Soluble adhesion molecules, spirometry, methacholine responsiveness and
peak flow variability was measured.
The group of patients with AA had higher levels of sE-selectin than the reference
group ðP ¼ 0:046Þ: Serum levels of sE-selectin correlated significantly with bronchial
responsiveness ðr ¼ 0:76Þ and peak flow variability ðr ¼ 0:75Þ ðPo0:01Þ in the NA but
not in the AA group. All adhesion molecules in AA ðPo0:05o0:001Þ; but only
sE-selectin in NA ðPo0:05Þ; were correlated to airway conductance. sVCAM-1
was reduced by inhaled steroids ðPo0:01Þ:
Our results indicate that endothelial cells are activated in asthma and that this
activity has a bearing on airflow variability and bronchial responsiveness in NA.
& 2004 Elsevier Ltd. All rights reserved.
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Introduction
Adhesion molecules such as the intercellular-adhe-
sion molecule-1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1) and E-selectin facilitate the
recruitment and migration of inflammatory cells
from the blood to the airway walls and therefore
have an important role in the pathogenesis of
asthma. Circulating forms of adhesion molecules
can be measured in blood. ICAM-1 and VCAM-1 are
shed from endothelial cells, epithelial cells and
monocytes while E-selectin is only released from
endothelial cells.1
Increased levels of circulating ICAM-1 and E-
selectin are found in exacerbations of asthma.2–5
Increased levels of soluble adhesion molecules are
also found in acute infections,1 in cystic fibrosis 6
and in pulmonary tuberculosis.7 In asthma sICAM-1
levels increase after allergen provocation 8 and
decrease after introduction of inhaled steroids.9
We have previously found that patients with
allergic (AA) and non-allergic asthma (NA) have
comparable bronchial responsiveness to methacho-
line. Patients with AA and NA differ, however, in
many other aspects such as responsiveness to cold
air, adenosine monophosphate (AMP),10 levels of
nitrogen oxide (NO) in expired air 11 and the level
of eosinophilic inflammation in the airways.12 This
implies that the mechanism through which bron-
chial responsiveness is developed is different in
these two sub-groups of asthma.
The aim of this study was to compare levels of
circulating adhesion molecules in patients with AA
and NA and to relate the levels of soluble adhesion
molecules to methacholine responsiveness and lung
function.
Population and methods
Patients
Nineteen patients with AA and 15 patients with NA
were included in this study 10,11 (Table 1). The
patients were recruited from the Department of
Respiratory Medicine and Allergology, at our hospi-
tal. Subjects were defined as having asthma; if they
had a physician diagnosed asthma and had pre-
viously demonstrated an increased responsiveness
to inhaled methacholine. The patients with asthma
had current respiratory symptoms and a forced
expiratory volume in 1 s (FEV1) above 70% of the
predicted value. Patients with asthma who had at
least one positive skin prick test (mean diame-
terX3mm) were defined as having AA. Skin prick
tests were carried out using Solu Prick (ALK,
Denmark) standardised allergen extract against
the following allergens: birch, timothy grass,
mugwort, cat, dog, horse, Dermatophagoides pter-
onyssinus, Cladosporium and Alternaria.
Fourteen of the allergic patients with asthma and
12 of the non-allergic patients with asthma were on
regular treatment with inhaled steroids (budeso-
nide 200–1600 mg ðn ¼ 21Þ or beclomethasone 50–
400 mg ðn ¼ 5Þ). Inhaled corticosteroid therapy was
continued with no changes. All the patients but one
with asthma were taking inhaled b2-agonists as
required. None of the patients was being treated
with theophylline compounds. One allergic subject
with asthma and six non-allergic subjects with
asthma were ex-smokers (stopped smoking 2–20
years previously).
Reference group
The control group comprised 17 subjects who
responded to a request for volunteers or were
recruited from the staff at our hospital; none had
asthmatic symptoms or was on anti-asthmatic
treatment and all were non-allergic 10,11 (Table 1).
All the investigated subjects were non-smokers
and free from respiratory infections for at least 6
weeks prior to the study and none had a history of
cardiovascular disease. The investigation was car-
ried out outside the birch and grass pollen season
(April–August) in all subjects.
The study was conducted in accordance with the
Declaration of Helsinki and was approved by the
Ethics Committee at the Medical Faculty at Uppsala
University. Verbal informed consent was obtained
prior to the study.
Measurement of circulation adhesion
molecules
Whole blood was drawn in SST tubes and allowed to
coagulate at room temperature for 60min. The
serum was then separated by centrifugation. After
collection the serum was frozen at 701C until
analysed. Soluble adhesion molecules were mea-
sured using commercial kits obtained from R&D
Systems (USA) according to the manufacturer’s
instructions. The sensitivity of the assays was
0.1 ng/l for sE-selectin, 0.35 ng/l for sICAM-1 and
2 ng/l for sVCAM-1.
Spirometry
The spirometry took place from 8.30 to 11 am.
The subjects were instructed not to take any
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short-acting b2-agonists 8 h before testing or any
long-acting b2-agonists 24 h before testing. Specific
airway conductance (sGaw), forced vital capacity
(FVC) and FEV1 were measured with a Masterlab
Trans spirometer and a Masterlab body plethysmo-
graph (Eric Jaeger AG, W .urzberg, Germany). Lung
function values are presented as a percentage of
reference values.13,14
Methacholine challenge
An automatic, inhalation dosimeter Spira Elektro 2
(Respiratory Care Centre, Hameenlinna, Finland),
was used in this study.15 The dosimeter was
adjusted with a nebulisation onset of 50ml and a
nebulisation duration of 1 s. Inspiratory flow rate
was 0.5 l/s. The dosimeter output was 1675 ml/
breath. Each individual took five tidal breaths of
each concentration and sGaw, FVC and FEV1 were
measured after 90 s. The next nebulising concen-
tration started 3min after the previous concentra-
tion had stopped. Baseline values were measured
after an inhalation of saline. After the nebulisation
of saline, methacholine chloride (National Corpora-
tion of Swedish Pharmacies) was delivered. The
starting concentration of methacholine was
0.0625mg/ml. The challenge was continued with
inhalation of doubling concentrations of methacho-
line until the FEV1 had decreased by 20% or the
highest concentration (32mg/ml of methacholine)
was reached. The quantity of inhaled methacholine
was calculated by weighing the amount of metha-
choline that was left in the dosimeter after each
concentration and subtracting it from the starting
dose.
The least-squares slope for methacholine was
calculated from the regression equation for per-
centage decline in FEV1 on the cumulative dose of
methacholine using all the measured points.16
Peak flow variability
Peak flow diaries were kept during a 17-day period,
starting on the day of inclusion in the study. The
peak expiratory flow rate (best of three measure-
ments) was recorded four times daily with a Mini-
Wright peak flow meter (Clement Clarke, London,
UK). Daily peak flow variability was calculated by
the formula: ((highest PEFlowest PEF) 100)/mean
PEF value of the day). Complete PEF-diaries were
obtained from all but three patients with AA and
one with NA.
Statistics
ANOVA and unpaired t-test was used to compare
the levels of soluble adhesion molecules between
the different patients groups and the reference
population. Linear regression was used to study the
relationship between bronchial responsiveness,
lung function and the level of soluble adhesion
molecules in the two groups of asthmatic patients.
The levels of soluble adhesion molecules and the
methacholine responsiveness slope was log trans-
formed before performing the analyses. In order to
avoid negative values the formula log(slopeþ 7)
was used when transforming the methacholine
responsiveness slope.
Results
The characteristics of the two patient groups and
the reference group are presented in Table 1. There
were no differences between the groups with AA
and NA. Both asthmatic groups had higher metha-
choline responsiveness and peak flow variabilty
than the reference group.
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Table 1 Demographics, lung function and medication in the reference and patient groups.
Healthy AA NA
(n¼ 17) (n¼ 19) (n¼ 15)
Age 37710 34711 39713
Women (n) 13 10 14
FEV1 (% pred) 95712 94715 90711
FVC1 (% pred) 9478 96714 9279
sGaw (% pred) 102752 81729 88760
Methacholine responsiveness (log transformed) 0.8170.42 1.4170.48*** 1.1670.24**
PEF variability (%) 5þ 2 774* 874**
Inhaled steroids (daily dose in mg) F 3827336 5207426
(mean7SD or N, *Po0.05, **Po0.01, ***Po0.001 compared to the reference group).
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The group of patients with AA had higher levels
of sE-selectin than the reference group ðP ¼ 0:046Þ:
A similar trend was also found between the NA
group and the reference group ðP ¼ 0:091Þ (Fig. 1).
No significant differences were found in the levels
of sICAM-1 or sVCAM-1 between any of the groups
(Fig. 2).
A significant correlation was found between sE-
selectin and bronchial responsiveness in the group
of patients with NA while no corresponding associa-
tion was seen in the AA group (Fig. 3). There was
also a significant correlation between sE-selectin
and peak flow variability in the NA but not in the AA
group (Fig. 4).
A significant correlation was found between sE-
selectin and sGaw in both asthmatic groups (Table
2). Significant correlations between sGaw and
sICAM-1 and sVCAM-1 were found in the AA but
not in the NA group. There were no significant
correlations between any of the soluble adhesion
molecules and FEV1 or FVC.
There was no correlation between age of the
patients or asthma duration and soluble adhesion
molecules in any of the asthmatic groups.
The influence of inhaled steroid dosage on the
level of soluble adhesion molecules was studied
with the two groups of asthmatics combined. A
dose-dependent decrease in the levels of sVCAM-1
with increasing steroid doses was found (Fig. 5).
Despite this no significant difference in the level of
sVCAM-1 was found between the diagnostic groups
after adjustment for inhaled steroid treatment.
No significant relation between steroid doses and
sE-selectin or sICAM-1 was found.
Discussion
The main findings in this study were that patients
with AA and NA in a stable phase tend to have
higher serum levels of sE-selectin than healthy
subjects whereas no differences in the other two
measured soluble adhesion molecules sICAM-1 and
sVCAM-1 was found. Higher level of sE-selectin was
related to decreased airway conductance in both
asthmatic groups whereas a relation between sE-
selectin and airflow variabilty and methacholine
responsiveness was only found in patients with NA.
The role of adhesion molecules in asthma is
supported by several studies showing an increased
expression of adhesion molecules in bronchial
epithelial and endothelial cells from asth-
matics.17,18 Increased eosinophil adhesion to
VCAM-1 and ICAM-1 has also been demonstrated in
patients with labile asthma 19 and during pollen
season in birch allergic subjects.20 The level of
soluble adhesion molecules in the circulation is
related to the turnover of these molecules on
the cell surface.21 Measuring soluble adhesion
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Figure 1 Levels of sE-selectin in healthy controls (H),
patients with AA and patients with NA (10th, 25th, 50th,
75th and 90th percentile, *Po0.05).
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Figure 2 Levels of sICAM-1 and sVCAM-1 in healthy
controls (H), patients with AA and patients with NA (10th,
25th, 50th, 75th and 90th percentile).
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molecules in serum has therefore been proposed as
a marker of inflammation in asthma and allergy.22
In the present study, we found no differences in
the serum levels of sICAM-1 and sVCAM-1 in any of
the asthma groups compared to the control group.
As the patients were in a clinically stable phase this
is in accordance with some previous studies,3,23,24
while others have found increased levels of sICAM-1
even in stable or mild asthma compared to
controls.4,5,25 A constant finding in previous studies
is that sICAM-1 levels are increased in acute
asthma 2–5,25 and thus to some extent related to
clinical asthma severity. In the present study,
higher sICAM-1 and sVCAM-1 levels were related
to decrease in airway conductance in the AA group,
while no other correlation was found between
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Figure 3 Correlation between sE-selectin and metha-
choline responsiveness (both variables are log trans-
formed).
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Figure 4 Correlation between sE-selectin and peak flow
variability (both variables are log transformed).
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these two soluble adhesion molecules and asthma
severity.
The levels of sE-selectin were higher in the
asthmatic population than in the reference group.
This is in contrast to previous studies where no
differences in sE-selectin levels were found be-
tween stable asthmatics and controls.3,5,23,24 The
differences were, however, small with a large
overlap between the asthmatic groups and the
reference group. Of greater interest is the finding
of fairly close correlations between sE-selectin
levels and airway lability (methacholine respon-
siveness and peak flow variability) in the non-
allergic asthmatic but not the allergic asthmatic
group. Soluble E-selectin is of special interest since
it probably is a specific marker of endothelial cell
activity,22 whereas sICAM-1 and sVCAM-1 are
released from both endothelial cells and mono-
cytes.1,26 Our results therefore indicate that
endothelial cell activity may play a greater role in
airflow variabilty and bronchial responsiveness in
NA than AA. The mechanism behind this is
uncertain, but could reflect the direct involvement
of endothelial cells in the development of airway
lability in NA. However, we have previously shown
that neutrophils are abundant in the airways of
patients with NA 12 and it is well established that
the expression of E-selectin on endothelial cells is
of major importance for the accumulation neutro-
phils in tissues. Our findings could therefore also
reflect a role of neutrophils in the development of
airway lability. A previous study showed correla-
tions between E-selectin and lung functions in
patients with COPD, another disease in which
neutrophils are abundant.23
The notion that adhesion molecules may have a
different role in AA than NA is not new. Several
studies have investigated this but the results have
been conflicting. Bentley et al. reported that there
was an increase in the staining of ICAM-1 and E-
selectin in the submucosa of intrinsic asthmatics
but not in extrinsic asthma.27 Gosset et al. found
the opposite with increased expression of adhesion
molecules in epithelial and endothelial cells in AA
but not NA.17 In accordance with the present study,
previous studies have showed similar serum levels
of sICAM-1 and sE-selectin in AA and NA.2,25
In our study, there was a significant correlation
between sVCAM-1 and the daily dosage of inhaled
steroids. In contrast with the results of Cenglizlier
et al. we found no correlation between inhaled
steroid treatment and sICAM-1.9 There was also no
correlation between sE-selectin and the daily dose
of inhaled steroids. VCAM-1 is selectively upregu-
lated by IL-4.28 The lower sVCAM-l levels in patients
with higher doses of inhaled steroids may therefore
be caused by a steroid-induced inhibition of IL-4
production.29
In conclusion NA patients with higher levels of sE-
selectin have increased airflow variability and
bronchial responsiveness, while this relationship
was not found in patients with AA. As sE-selectin is
a marker of endothelial activity, our results
indicate that endothelial cell activity may play a
greater role in airflow variabilty and bronchial
responsiveness in NA than AA.
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Table 2 Correlation (r-values) between specific
airway conductance (sGAW) and soluble adhesion
molecules.
Allergic
asthma
Non-allergic
asthma
sE-selectin 0.77*** 0.60*
sICAM-1 0.50* 0.26
sVCAM-1 0.51* 0.19
(*Po0.05, ***Po0.001).
600
400
200
<200    200-400 >400
800
sVCAM-1
µg
/L
**
Inhaled steroid
(µg/day)
Figure 5 Levels of sVCAM-1 in relation to the daily dose-
inhaled steroids (budesonide or beclomethasone (10th,
25th, 50th, 75th and 90th percentile, **Po0.01).
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